Search

Cookies

We use cookies to improve your experience. By continuing, you accept our use of cookies.

Business

Hospital Stocks Plunge After Supreme Court Questions Medicine Price Markups

· · 2 min read

Shares of major Indian hospital groups, including Apollo and Fortis, saw significant declines today. The fall follows strong remarks from the Supreme Court questioning excessive markups on medicines and suggesting a uniform 16% trade margin.

Shares of several prominent Indian hospital companies experienced sharp declines in Wednesday's trading session, reacting to recent strong remarks from the Supreme Court regarding medicine pricing. Major players like Yatharth Hospital & Trauma Care Services, Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences (KIMS), Fortis Healthcare, and Max Healthcare Institute were among the biggest decliners.

Yatharth Hospital shares slumped by 5.92%, Apollo Hospitals declined 5.69%, KIMS shares plunged 5.49%, Fortis Healthcare dropped 4.81%, and Max Healthcare slipped 4.55%. Other hospital stocks, including Manipal Health Enterprises and Rays of Belief Ltd, also saw significant drops, ranging from 4.47% to 4.39%.

Supreme Court Questions Medicine Markups

The market downturn for hospital stocks comes a day after the Supreme Court voiced serious concerns over the steep markups on medicines sold through corporate hospitals. During a hearing, the top court was informed that a particular cancer medicine, supplied to retailers for Rs 2,700, was being sold to patients with an exorbitant Maximum Retail Price (MRP) of Rs 27,000.

Justices Vikram Nath and Sandeep Mehta strongly criticized this practice, stating, "This is carnage. Plain and simple." The bench questioned the rationale behind varying trade margins on different medicines and suggested that the Centre consider implementing a uniform 16% margin on all pharmaceutical drugs.

Impact on Patients and Policy Suggestions

Furthermore, the Supreme Court urged the Centre to investigate the common practice where corporate hospitals mandate patients to purchase medicines exclusively from their in-house chemists or specified pharmacies. The court observed that such practices ultimately burden patients and taxpayers, particularly those whose medical treatments are covered under various government healthcare schemes.

The court's intervention underscores a broader scrutiny of healthcare costs and transparency within the sector, potentially signaling future regulatory changes that could impact hospital revenues and profitability, thus influencing investor sentiment.

Related